Gene-Edited cells could stop bleeding in severe hemophilia b
Disease control
Recruiting now
This study tests a single dose of BE-101, a treatment made from a person's own blood cells that are gene-edited to produce clotting factor IX. It is for 24 adult men with moderately severe or severe hemophilia B who currently use preventive factor IX infusions. The goal is to see…
Phase: PHASE1, PHASE2 • Sponsor: Be Biopharma • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC